<DOC>
	<DOCNO>NCT02750007</DOCNO>
	<brief_summary>This study conduct China . The aim trial ass tolerability HS-20004 titration administration type 2 diabetic patient .</brief_summary>
	<brief_title>Tolerability HS-20004 With Titration Administration Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes diagnose 3 month ; HbA1c ≥6.0 ≤9.0 % , FPG ≥7.0 ≤13.9 mmol/L ; Body Mass Index ( BMI ) 18.5 30 kg/m^2 ( inclusive ) total body weight least 50 kg ; Agree stop drug diabetes washout study period ; Treatment GLP1 analogue , DPPIV enzyme inhibitor analogue ; History family history drug allergy ; Smoker alcohol abuse ; Currently use plan use systemic corticosteroid ; History recurrent severe hypoglycemia ; History proliferative retinopathy maculopathy require acute treatment ; Impaired hepatic renal function , cardiac problem ; Uncontrolled active untreated hypertension ; Family history thyroid cancer submandibular gland cancer , past history pancreatitis , cholelithiasis , serious unconscious hypoglycemia history ; Positive hepatitis B surface antigen , hepatitis C antibody , HIV antibody syphilis antibody ; Subject participate investigational study within 3 month , currently participate another clinical study ; Female subject childbearing potential use acceptable method birth control , pregnant planning pregnancy , breastfeeding , male subject use acceptable method birth control , within six month randomization ; Subject refrain smoking , eat and/or drink contain xanthine/caffeine , strenuous exercise , others affect drug absorption , distribution , metabolism excretion within 2 day study drug administration ; Have medical abnormality ( cardiovascular , hepatic , renal , gastrointestinal , immunologic , hematological , hormonal , metabolic , neoplasmatic mental disease ) , opinion investigator , might affect absorption , distribution , metabolism , excretion study drug , prevent patient follow complete protocol； Subject use study determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>